Close Menu
Home › Eli Lilly's Selpercatinib Shows Strong Activity in RET Fusion-Positive NSCLC

Eli Lilly's Selpercatinib Shows Strong Activity in RET Fusion-Positive NSCLC

Sep 09, 2019
|
staff reporter

NEW YORK – In the Phase I/II LIBRETTO-001 study, 68 percent of 105 heavily pretreated non-small cell lung cancer patients with RET fusions saw their tumors shrink after treatment with Eli Lilly's investigational RET inhibitor selpercatinib, researchers reported today at the World Conference on Lung Cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
03
Featured Webinar

Streamlined and High-Precision Cancer Analysis Using an Automated NGS Workflow in the Reference Lab Setting

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10
Featured Webinar

Laboratory Validation of a Kit-Based Liquid Biopsy NGS Assay

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
21
Featured Webinar

Broad Genomic Testing for Oncology Clinical Trials and Clinical Practice

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

What's Popular?

In Cancer

  1. European Labs Continue to Validate, Implement TMB, Facing Down Cutoff Discordance Concerns

    Premium

  2. UK-Led Team Pushes for Broader BRCA Screening Policies With Data on Ashkenazi Population

    Premium

  3. Repare Therapeutics Using CRISPR to Develop Cancer Treatments for Synthetic Lethal Targets

    Premium

  4. Roche's Tecentriq Demonstrates Survival Benefit in PD-L1 High NSCLC

  5. Keytruda Plus Chemotherapy Extends Survival in NSCLC Patients Lacking PD-L1 Expression

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.